Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scinai Immunotherapeutics Ltd SCNI

Healthcare Biotechnology
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various... see more

Recent & Breaking News (NDAQ:SCNI)

BiondVax to Present on October 8 at the Aegis Growth Conference

PR Newswire October 6, 2015

BiondVax Establishes Capability for the Manufacture of Clinical Grade Universal Flu Vaccine for Phase III Clinical Trials

PR Newswire October 1, 2015

BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak

PR Newswire September 30, 2015

BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference

PR Newswire September 8, 2015

BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health

PR Newswire September 2, 2015

BiondVax to Initiate the Process for Trading the Company's Shares in the US through ADR

PR Newswire April 2, 2014